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Learning Objectives
® Identify advantages and challenges associated with telehealth for
the treatment of SUDs
® Review existing literature related to the impact of telehealth upon
engagement and treatment retention
® Summarize legal requirements that impact SUD telehealth
treatment
® Outline state-based efforts as a model for advocating for
increasing access to care
® Discuss clinical skills for challenging cases
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Introduction and Background
® Models of care for substance use disorder (SUD) treatment
have traditionally required face-to-face visits
® COVID-19 provided a catalyst for change and brought
telehealth to the SUD clinic
® An enforcement waiver of telehealth rules during the
pandemic allowed for previously prohibited practices
® Telehealth has increased access to care for many, but barriers
and challenges remain
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Defining Terms
® Telehealth or Telemedicine: a mechanism of healthcare delivery
using interactive technology to allow patient‐physician interaction
® Synchronous vs asynchronous
® Audiovisual vs audio only

® Telehealth is commonly used for many types of patient care
® Is there a compelling reason to consider SUD differently from other chronic

illnesses?
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Lessons Learned: IDD Patient Care
® Ohio’s Telepsychiatry project through WSU has
been serving patients with an intellectual or
developmental disability across the state of Ohio
® Improved access to psychiatric care for over 1800
patients that might not otherwise be available
(e.g., in rural areas)
® Benefits
® Allowed for a team-based approach
® Reduced transportation barriers

®Telehealth is effective
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Lessons Learned: Resident Therapy
® Resident psychotherapy clinic
® Over 100 patients seen for weekly psychotherapy
® Predominantly psychodynamic psychotherapy

® In‐person to virtual transition
® Prior to 2020, psychodynamic therapy was rarely done virtually
® Many dynamic therapists previously believed that effective

psychodynamic therapy could only be performed in person
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Lessons Learned from Psychotherapy
® Nonverbal components
®

Eye contact, emotional expression

® Transference and interpretations
®

Avoidance via telehealth

® Importance of frame and structure
®

Confidential place, presence

®Telehealth is effective
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Telehealth for SUD: Considerations
® Choosing telehealth:
® Rarely are clinics selecting between telehealth and in-person care

® Often the choice is between telehealth and no care
Especially true in the context of a pandemic
® Continues to be true for some populations
®

® Rapid increase in availability and necessity of telehealth since
early 2020
®

The systems we are using have been generally hastily built and rolled out
as quickly as possible

® What would a systematic, coordinated effort and planned
structure look like?
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Telehealth for SUD: Logistics
® Internet access
® 83-95% of patients have access to smartphone (Masson et al, 2019)
® Free internet available in many public places, but confidentiality is limited

® Platforms
® Wide variety of quality
® Consist of video and audio connection between patient and provider
® Access remotely, making it easier for provider/patient/support staff to be in different

locations
® Providers can work remotely

® Scheduling
® Flexibility
® Potentially easier to see appointments back-to-back or in smaller windows
® Show rate affected?
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Telehealth for SUD: Drawbacks
® Connectivity, patient distraction, less confidential settings, more reliance
on subjective report
® Providers and patients may feel more isolated
® Increased administrative burden on providers
® UDS, Labs, physical exam are done asynchronously
® Less objective data overall, regulatory requirements for testing
® Communication with nursing and other staff support
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Telehealth for SUD: Benefits
® Convenience
® Reduced stigma
® Seeing patients in their home environments with their support available
® Improved access for those with limited transportation, time,
employment, childcare barriers
® Qualitative studies corroborate this (Uscher‐Pines et al., 2020)

® Shifting from emphasis on accountability to engagement and
flexibility
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Outcomes Evidence
® There is limited data related to health outcomes in patients with SUD
who utilize telehealth.
® Prior to the pandemic, a systematic review from 2019 revealed that
telehealth is associated with high patient satisfaction (Lin et al, 2019)
® Telephone-based visits were was found to be feasible for patients with
opioid use disorder (OUD) on buprenorphine therapy (Mehtani et al.,
2021).
® A retrospective cohort study examined 28,791 Veterans diagnosed
with OUD treated with buprenorphine across all VA facilities between
2008 and 2017 and found a lower risk for treatment discontinuation in
those who engaged in telehealth compared to in-person visits.
(Vakkalanka et al., 2021)
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OneFifteen Telehealth Study
® We conducted a retrospective analysis among adult SUD patients
(n = 1,088) between October 2020 and August 2021.
® Using a retrospective cohort design, we estimated the
likelihood of treatment dropout comparing patients who
used telehealth with video, telephone, or primarily in-person
services.
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OneFifteen Telehealth Study
® The results of our study found that patients who used
telehealth with video had 3.7 times greater odds of
remaining engaged in treatment for 90 days or longer,
compared to in-person patients.
® Patients who used telehealth with video had a lower likelihood of

dropout compared to patients who used both in‐person and
telephone‐based services.
® We found that patients who received in‐person care were older, more
likely to be homeless, unemployed, diagnosed with OUD.
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Case 1
●

●

●

●

●

A 27-year-old patient is scheduled for a follow up appointment
via telehealth in your outpatient clinic.
She was diagnosed with methamphetamine use disorder
about three weeks ago.
She logs onto the telehealth platform and appears distressed
and paranoid.
She says that her ex-boyfriend hacked into her computer and
stole her password.
She appears thin and disheveled.
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Discussion: Case 1
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Pre-Pandemic Federal Regulatory Context
Harrison Act

Drug Addiction Treatment Act

(Indirect) enforcement of anti-maintenance
policies; black markets develop; difficult to
treat addiction remaining relatively easy to
create iatrogenic addiction

Established process for physicians to
prescribe schedule III-V CS (buprenorphine)
for opioid use disorder. Intended to allow for
“office-based” treatment (e.g. outside of an
OTP)

1970
1914

2008
2002

Controlled Substances Act
Established Scheduled I-V for CS
Expanded Federal authority in enforcement of
drug policy

Ryan Haight Act
Requires in-person examination before
issuing a controlled substance prescription
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Ohio Rules
® Pre-pandemic:
® Ohio Administrative Code sec. 4731-11-09(A):
® A physician cannot prescribe a controlled substance to a person on whom

the physician has never conducted a physical examination, unless one of a
limited category of exceptions applies.

® Office-based opioid treatment (OBOT)
® During Public Health Emergency (PHE):
® Effective March 9, 2020, and currently expiring March 31, 2022, providers

are permitted to use telemedicine in place of in-person visits. Includes:
prescribing for controlled substances and office-based treatment for opioid
addiction
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●
●

Ohio HB122 - moves telehealth more into mainstream of health care delivery options in Ohio
Ohio rule 4731-11-09(A): “...a physician shall not prescribe... any controlled substance to a person on
whom the physician has never conducted an in-person physical examination.”

March, 2020

Medical Board suspended the enforcement of 4731-11-09(A)
Ohio Public Health Emergency

June, 2021

Medical Board reinstated the enforcement of 4731-11-09(A)
To be made effective September 17, 2021

August, 2021

Medical Board re-suspended the enforcement of 4731-11-09(A)

November, 2021

Medical Board extended suspension of enforcement of 4731-11-09(A)

Ongoing Efforts

Until December 31, 2021

Until March 31, 2022

Telehealth advocacy: moving to maintain suspension of
enforcement indefinitely
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Future of
Legal Landscape?

#ASAMAnnual2022

Case 2
® A 34-year-old patient previously established in your addiction
clinic returns to using fentanyl daily.
® He calls your office and requests to restart buprenorphine
treatment for opioid use disorder.
® His last use of fentanyl was only a few hours ago and he is
not yet in withdrawal.
® Several months ago, he was accused by a group member of
"offering to sell Suboxone."
® He requests to use telehealth for this appointment.
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Discussion: Case 2
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Case 3
●

●

●
●

47 yo patient with a history of alcohol use disorder
presents for an intake, requested the appointment be virtual
Desires to quit daily drinking and has had nothing to drink in
the past 24 hrs. No recent evaluation or labs.
1 past ER visit while withdrawing from alcohol
Patient reports anxiety, shakiness, nausea, vomiting x1
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Discussion: Case 3
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Final Takeaway Points / Summary
® We still have a lot to learn / data to collect
® The field of addiction medicine embraces meeting people where they are at
® Treatment “success” and “recovery” is individualized
® The pandemic brought about a different perspective on how rigidly we used
to practice because of the rules and regulations that were imposed upon us.
® Telehealth readiness / comfort level ‐ needs to be continuously reassessed
® Regulatory considerations – we need to remain aware of the regulations that
govern our work and continue to look for opportunities to exert influence
toward creating a system that allows access to evidence based treatments.
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Questions?
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